Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;23(6):1037-1057.
doi: 10.1007/s10198-021-01407-9. Epub 2021 Dec 2.

Willingness-to-pay for cancer treatment and outcome: a systematic review

Alene Sze Jing Yong  1 , Yi Heng Lim  2 , Mark Wing Loong Cheong  1 , Ednin Hamzah  3 , Siew Li Teoh  4
Affiliations

Willingness-to-pay for cancer treatment and outcome: a systematic review

Alene Sze Jing Yong et al. Eur J Health Econ. 2022 Aug.

Abstract

Background: Understanding patient preferences in cancer management is essential for shared decision-making. Patient or societal willingness-to-pay (WTP) for desired outcomes in cancer management represents their preferences and values of these outcomes.

Objective: The aim of this systematic review is to critically evaluate how current literature has addressed WTP in relation to cancer treatment and achievement of outcomes.

Methods: Seven databases were searched from inception until 2 March 2021 to include studies with primary data of WTP values for cancer treatments or achievement of outcomes that were elicited using stated preference methods.

Results: Fifty-four studies were included in this review. All studies were published after year 2000 and more than 90% of the studies were conducted in high-income countries. Sample size of the studies ranged from 35 to 2040, with patient being the most studied population. There was a near even distribution between studies using contingent valuation and discrete choice experiment. Based on the included studies, the highest WTP values were for a quality-adjusted life year (QALY) ($11,498-$589,822), followed by 1-year survival ($3-$198,576), quality of life (QoL) improvement ($5531-$139,499), and pain reduction ($79-$94,662). Current empirical evidence suggested that improvement in QoL and pain reduction had comparable weights to survival in cancer management.

Conclusion: This systematic review provides a summary on stated preference studies that elicited patient preferences via WTP and summarised their respective values. Respondents in this review had comparable WTP for 1-year survival and QoL, suggesting that improvement in QoL should be emphasised together with survival in cancer management.

Keywords: Cancer treatment; Contingent valuation; Discrete choice experiment; Quality of life; Stated preference; Systematic review; Willingness to pay.

PubMed Disclaimer

References

    1. Wang, H., Naghavi, M., Allen, C., Barber, R.M., Bhutta, Z.A., Carter, A., et al.: Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 388(10053), 1459–1544 (2016). https://doi.org/10.1016/S0140-6736(16)31012-1 - DOI
    1. Knaul, F.M., Farmer, P.E., Krakauer, E.L., De Lima, L., Bhadelia, A., Jiang Kwete, X., et al.: Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. The Lancet. 391(10128), 1391–1454 (2018). https://doi.org/10.1016/s0140-6736(17)32513-8 - DOI
    1. Yabroff, K.R., Lund, J., Kepka, D., Mariotto, A.: Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol. Biomark. Prev. 20(10), 2006–2014 (2011). https://doi.org/10.1158/1055-9965.EPI-11-0650 - DOI
    1. Luengo-Fernandez, R., Leal, J., Gray, A., Sullivan, R.: Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 14(12), 1165–1174 (2013). https://doi.org/10.1016/S1470-2045(13)70442-X - DOI - PubMed
    1. Rocque, G.B., Rasool, A., Williams, B.R., Wallace, A.S., Niranjan, S.J., Halilova, K.I., et al.: What is important when making treatment decisions in metastatic breast cancer? A qualitative analysis of decision-making in patients and oncologists. Oncologist. 24(10), 1313–1321 (2019). https://doi.org/10.1634/theoncologist.2018-0711 - DOI - PubMed - PMC

Publication types

LinkOut - more resources